FASTinov SA

medical devices

About

FASTinov SA is a biotech company founded in 2013 as a spin-off from the University of Porto. The company specializes in ultra-rapid antimicrobial susceptibility testing (AST) using patented technology that provides results within 2 hours, significantly faster than traditional methods. Led by CEO Cidália Pina-Vaz, FASTinov focuses on improving clinical decision-making in infectious diseases, particularly sepsis. The company offers CE-marked AST kits that utilize flow cytometry to detect bacterial lesions caused by antibiotics. These kits enable rapid susceptibility profiling from positive blood cultures, urine, or bacterial/yeast colonies. By providing timely and reliable results, FASTinov aims to enhance patient outcomes, reduce healthcare costs, and help combat antimicrobial resistance. Its solutions are primarily targeted at clinical microbiology laboratories and hospitals, supporting faster, evidence-based treatment decisions for severe infections.

Technologies

Outlook Microsoft Office 365 Google Font API Google Maps Google Maps (Non Paid Users) Bootstrap Framework Mobile Friendly WordPress.org Apache Google Tag Manager Nginx Hubspot

Keywords

next generation idast microbiology flow cytometry antimicrobial susceptibility testing antimicrobial resistance invitro diagnostics amr nextgeneration ast sepsis rapid blood culture testing phenotypic resistance detection ce-marked ast kits antibiogram resistance detection flow cytometry in microbiology diagnostic innovation services sepsis management esbl detection bacterial resistance mechanisms bacterial strains validation phenotypic susceptibility antimicrobial resistance combat susceptibility report in 2 hours disruptive diagnostic technology bloodstream infections fluorescent probe technology flow cytometry-based antibiogram microbial cell lesions broad-spectrum antibiotics

Location

455 Rua Alfredo Allen, Porto, Porto District, Portugal, 4200-135

Related Companies

Companies in the same industry